Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy

Autor: Polychronis Pavlidis, Anastasia Tsakmaki, Eirini Pantazi, Katherine Li, Domenico Cozzetto, Jonathan Digby- Bell, Feifei Yang, Jonathan W. Lo, Elena Alberts, Ana Caroline Costa Sa, Umar Niazi, Joshua Friedman, Anna K. Long, Yuchun Ding, Christopher D. Carey, Christopher Lamb, Mansoor Saqi, Matthew Madgwick, Leila Gul, Agatha Treveil, Tamas Korcsmaros, Thomas T. Macdonald, Graham M. Lord, Gavin Bewick, Nick Powell

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)

Mechanisms of non-response to ustekinumab, a biologic targeting IL-23, are currently unclear. Here, the authors show that the transcriptional program regulated by IL-22, an IL-23 responsive cytokine, is enriched in patients with ulcerative colitis un

Externí odkaz: https://doaj.org/article/09b1e8f2868c4b6694a41d33bf89af3b

792: MICROBIOTA-RESPONSIVE CYTOTOXIC, POLYFUNCTIONAL CD4+ T CELLS ARE ENRICHED IN ULCERATIVE COLITIS AND ARE ASSOCIATED WITH RESISTANCE TO ANTI-CYTOKINE THERAPIES

Autor: Sherine Hermangild Kottoor, Domenico Cozzetto, Matthew Madgwick, Marton Olbei, Jonathan W. Lo, Jonathan Digby-Bell, Hajir Ibraheim, Laura E. Constable, Polychronis Pavlidis, Tamas Korcsmaros, Nick Powell

Publikováno v: Gastroenterology. 162:S-191

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::629fd621786423c4fd071ec069dd6abd
https://doi.org/10.1016/s0016-5085(22)60458-x

Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells

Autor: Behdad Afzali, Joshua R. Friedman, Domenico Cozzetto, Svetlana Saveljeva, Feifei Yang, Anastasia Tsakmaki, Rami Mohamed, Tsui Tjir-Li, Katherine Li, Emilie Stolarczyk, Thomas T. MacDonald, Aimee Parker, Polychronis Pavlidis, Carmen Pin, Gavin A. Bewick, Arthur Kaser, Eirini Pantazi, Danielle Minns, Graham M. Lord, Nick Powell, Jonathan Digby-Bell, Paul Lavender

Publikováno v: Powell, N, Pantazi, E, Pavlidis, P, Tsakmaki, A, Li, K, Yang, F, Parker, A, Pin, C, Cozzetto, D, Minns, D, Stolarczyk, E, Saveljeva, S, Mohamed, R, Lavender, P, Afzali, B, Digby-Bell, J, Tjir-Li, T, Kaser, A, Friedman, J, MacDonald, T T, Bewick, G A & Lord, G M 2020, ' Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells ', Gut, vol. 69, no. 3, pp. 578-590 . https://doi.org/10.1136/gutjnl-2019-318483
Gut

ObjectiveThe functional role of interleukin-22 (IL22) in chronic inflammation is controversial, and mechanistic insights into how it regulates target tissue are lacking. In this study, we evaluated the functional role of IL22 in chronic colitis and p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07bf319025277996258c2281217598b7
https://kclpure.kcl.ac.uk/ws/files/120861462/gutjnl_2019_318483.full.pdf

Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review

Autor: Lee Kellingray, Ian L P Beales, Simon D. Goldenberg, Jonathan Digby-Bell, Ngozi Franslem-Elumogo, Arjan Narbad, Rahul Batra, Peter M. Irving

Publikováno v: Infectious Diseases and Therapy

Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI). There have been many well-conducted randomized controlled trials and thousands o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bdb9a89f06c36ee25e35d8c10fce02a
https://doi.org/10.1007/s40121-018-0189-y

Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience

Autor: Peter M. Irving, Hajir Ibraheim, Jonathan Digby-Bell, A Ibarra, Ailsa Hart, Nick Powell, Ashish Srinivasan, Philip Oppong, Elisabeta Compot, Klaartje Kok, Irena Norman, Julia Biedermann, Gareth Parkes, Oliver Brain, Miles Parkes, Mark A Samaan, Issrah Jawad, Bu'Hussain Hayee, Jonathan Segal, Joanna Rimmer

Publikováno v: Annals of Gastroenterology

Background The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may be advantageous in older patients at greater risk of treatment-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5fe8c3891b031ea9b6d9579f396146c
https://pubmed.ncbi.nlm.nih.gov/32127738